Hitting a New Target in Multiple Myeloma.

ONCOLOGY sat down with Sagar Lonial, MD, professor and chair of Hematology and Medical Oncology at the Emory University School of Medicine and chief medical officer at Emory's Winship Cancer Institute, to discuss the FDA approval of the antibody-drug conjugate belantamab mafodotin, along with other BCMA-targeting agents for patients with multiple myeloma.